## Giulietta Venturi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6739858/publications.pdf

Version: 2024-02-01

68 4,714 23 62 g-index

73 73 73 73 8282

times ranked

citing authors

docs citations

all docs

#	Article	IF	Citations
1	Lack of Evidence of Chikungunya Virus Infection among Blood Donors during the Chikungunya Outbreak in Lazio Region, Italy, 2017. Viruses, 2022, 14, 619.	1.5	2
2	Dengue and Chikungunya virus circulation in Cameroon and Gabon: molecular evidence among symptomatic individuals. Access Microbiology, 2022, 4, .	0.2	1
3	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nature Communications, 2021, 12, 2670.	5.8	297
4	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. Frontiers in Immunology, 2021, 12, 750386.	2.2	6
5	West Nile virus in Europe: after action reviews of preparedness and response to the 2018 transmission season in Italy, Slovenia, Serbia and Greece. Globalization and Health, 2020, 16, 47.	2.4	18
6	Specialist laboratory networks as preparedness and response tool - the Emerging Viral Diseases-Expert Laboratory Network and the Chikungunya outbreak, Thailand, 2019. Eurosurveillance, 2020, 25, .	3.9	4
7	Dengue fever complicated by liver dysfunction due to possible co-infection with hepatitis E in a returning traveller from Cuba. Infezioni in Medicina, 2020, 28, 98-103.	0.7	O
8	Inhibitory effect of Ocotea quixos (Lam.) Kosterm. and Piper aduncum L. essential oils from Ecuador on West Nile virus infection. Plant Biosystems, 2019, 153, 344-351.	0.8	11
9	Seroprevalence of West Nile and dengue virus in the human population of the Bolivian Chaco. Journal of Medical Virology, 2019, 91, 146-150.	2.5	2
10	Secondary Autochthonous Outbreak of Chikungunya, Southern Italy, 2017. Emerging Infectious Diseases, 2019, 25, 2093-2095.	2.0	20
11	Epidemiological and clinical suspicion of congenital Zika virus infection: Serological findings in mothers and children from Brazil. Journal of Medical Virology, 2019, 91, 1577-1583.	2.5	7
12	The Italian 2017 Outbreak Chikungunya Virus Belongs to an Emerging Aedes albopictus–Adapted Virus Cluster Introduced From the Indian Subcontinent. Open Forum Infectious Diseases, 2019, 6, ofy321.	0.4	39
13	Laboratory findings in Zika infection: The experience of a reference centre in North-West Italy. Journal of Clinical Virology, 2018, 101, 18-22.	1.6	O
14	An early start of West Nile virus seasonal transmission: the added value of One Heath surveillance in detecting early circulation and triggering timely response in Italy, June to July 2018. Eurosurveillance, 2018, 23, .	3.9	45
15	Prevalence of Usutu and West Nile virus antibodies in human sera, Modena, Italy, 2012. Journal of Medical Virology, 2018, 90, 1666-1668.	2.5	20
16	Vector competence of Italian Aedes albopictus populations for the chikungunya virus (E1-226V). PLoS Neglected Tropical Diseases, 2018, 12, e0006435.	1.3	19
17	Vector competence of Aedes albopictus for the Indian Ocean lineage (IOL) chikungunya viruses of the 2007 and 2017 outbreaks in Italy: a comparison between strains with and without the E1:A226V mutation. Eurosurveillance, 2018, 23, .	3.9	17
18	Sensitivity and Kinetics of an NS1-Based Zika Virus Enzyme-Linked Immunosorbent Assay in Zika Virus-Infected Travelers from Israel, the Czech Republic, Italy, Belgium, Germany, and Chile. Journal of Clinical Microbiology, 2017, 55, 1894-1901.	1.8	63

#	Article	IF	Citations
19	Imported arboviral infections in Italy, July 2014-October 2015: a National Reference Laboratory report. BMC Infectious Diseases, 2017, 17, 216.	1.3	21
20	Status, quality and specific needs of Zika virus (ZIKV) diagnostic capacity and capability in National Reference Laboratories for arboviruses in 30 EU/EEA countries, May 2016. Eurosurveillance, 2017, 22, .	3.9	10
21	Detection of a chikungunya outbreak in Central Italy, August to September 2017. Eurosurveillance, 2017, 22, .	3.9	149
22	First detection of Zika virus infection in a Croatian traveler returning from Brazil, 2016. Journal of Infection in Developing Countries, 2017, 11, 662-667.	0.5	2
23	Recent Chikungunya Virus Infection in 2 Travelers Returning from Mogadishu, Somalia, to Italy, 2016. Emerging Infectious Diseases, 2016, 22, 2025-2027.	2.0	8
24	West Nile virus transmission: results from the integrated surveillance system in Italy, 2008 to 2015. Eurosurveillance, 2016, 21, .	3.9	74
25	Authors' reply: diagnostic challenges to be considered regarding Zika virus in the context of the presence of the vector Aedes albopictus in Europe. Eurosurveillance, 2016, 21, 30163.	3.9	9
26	Experimental studies of susceptibility of Italian Aedes albopictus to Zika virus. Eurosurveillance, 2016, 21, .	3.9	105
27	Experimental investigation of the susceptibility of Italian Culex pipiens mosquitoes to Zika virus infection. Eurosurveillance, 2016, 21, .	3.9	47
28	An autochthonous case of Zika due to possible sexual transmission, Florence, Italy, 2014. Eurosurveillance, 2016, 21, 30148.	3.9	178
29	TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. Oncogene, 2015, 34, 5163-5174.	2.6	69
30	Anti-tick-borne encephalitis (TBE) virus neutralizing antibodies dynamics in natural infections versus vaccination. Pathogens and Disease, 2015, 73, 1-3.	0.8	14
31	Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Letters, 2015, 356, 697-703.	3.2	81
32	Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer and Metastasis Reviews, 2014, 33, 1095-1108.	2.7	146
33	Exosomes released in vitro from Epstein–Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs. Cancer Letters, 2013, 337, 193-199.	3.2	78
34	Prevalence of antibodies to phleboviruses and flaviviruses in Peja, Kosovo. Clinical Microbiology and Infection, 2011, 17, 1180-1182.	2.8	12
35	pHâ€dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. International Journal of Cancer, 2010, 127, 207-219.	2.3	237
36	Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death and Disease, 2010, 1, e87-e87.	2.7	155

#	Article	IF	CITATIONS
37	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PLoS ONE, 2009, 4, e5219.	1.1	806
38	Humoral immunity in natural infection by tickâ€borne encephalitis virus. Journal of Medical Virology, 2009, 81, 665-671.	2.5	18
39	Arboviral infections in Egyptian and Sardinian children and adults with aseptic meningitis and meningo-encephalitis. Scandinavian Journal of Infectious Diseases, 2009, 41, 898-899.	1.5	2
40	Occupational risk associated with Toscana virus infection in Tuscany, Italy. Occupational Medicine, 2008, 58, 540-544.	0.8	8
41	Genetic variability of the M genome segment of clinical and environmental Toscana virus strains. Journal of General Virology, 2007, 88, 1288-1294.	1.3	15
42	Detection of Toscana virus central nervous system infections in Sardinia Island, Italy. Journal of Clinical Virology, 2007, 40, 90-91.	1.6	20
43	Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet, The, 2007, 370, 1840-1846.	6.3	1,268
44	Humoral immunity and correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis virus in children. Journal of Virological Methods, 2006, 134, 136-139.	1.0	13
45	Unusual Presentation of Lifeâ€Threatening Toscana Virus Meningoencephalitis. Clinical Infectious Diseases, 2004, 38, 515-520.	2.9	84
46	Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. Journal of Antimicrobial Chemotherapy, 2004, 53, 356-360.	1.3	36
47	Detection of a Drug-Resistant Human Immunodeficiency Virus Variant in a Newly Infected Heterosexual Couple. Clinical Infectious Diseases, 2002, 34, 116-117.	2.9	10
48	Broad Nucleosideâ€Analogue Resistance Implications for Human Immunodeficiency Virus Type 1 Reverseâ€Transcriptase Mutations at Codons 44 and 118. Journal of Infectious Diseases, 2002, 185, 898-904.	1.9	46
49	Treatment with Lopinavir/Ritonavir in Heavily Pretreated Subjects Failing Multiple Antiretroviral Regimens in Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 533-535.	0.9	11
50	Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type $1$ protease and reverse transcriptase inhibitors. Journal of Clinical Virology, 2002, 25, 57-62.	1.6	20
51	Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. Journal of Medical Virology, 2002, 66, 143-150.	2.5	33
52	Divergent Distribution of HIV-1 Drug-Resistant Variants on and off Antiretroviral Therapy. Antiviral Therapy, 2002, 7, 245-250.	0.6	27
53	Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy., 2000, 60, 294-299.		15
54	Ultrasensitive in-house reverse transcription-competitive PCR for quantitation of HIV-1 RNA in plasma. Journal of Virological Methods, 2000, 87, 91-97.	1.0	11

#	Article	IF	CITATIONS
55	Antiretroviral Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Protease from Paired Cerebrospinal Fluid and Plasma Samples. Journal of Infectious Diseases, 2000, 181, 740-745.	1.9	106
56	Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. Aids, 2000, 14, 2204.	1.0	18
57	Evaluation of Cellâ€Free and Cellâ€Associated Peripheral Blood Human Immunodeficiency Virus Type 1 RNA Response to Antiretroviral Therapy. Journal of Infectious Diseases, 1999, 179, 361-366.	1.9	18
58	Genotypic Resistance to Zidovudine as a Predictor of Failure of Subsequent Therapy with Human Immunodeficiency Virus Type-1 Nucleoside Reverse-Transcriptase Inhibitors. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 274-282.	1.3	15
59	Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients., 1999, 57, 140-144.		33
60	Development and Significance of the HIV-1 Reverse Transcriptase M184V Mutation During Combination Therapy With Lamivudine, Zidovudine, and Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 203.	0.9	19
61	Clinical Evaluation of an In-House Reverse Transcription-Competitive PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma. Journal of Clinical Microbiology, 1999, 37, 333-338.	1.8	10
62	Heterozygosity for the CCR-5 $\hat{l}$ "32 deletion, HIV-1 transmission and disease progression. Clinical Microbiology and Infection, 1998, 4, 351-353.	2.8	0
63	Lack of efficacy of ozone therapy in HIV infection. Clinical Microbiology and Infection, 1998, 4, 667-669.	2.8	7
64	Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Molecular Biotechnology, 1998, 10, 1-8.	1.3	22
65	Lack of Evidence of HHV-8 DNA in Blood Cells From Heart Transplant Recipients. Blood, 1997, 89, 1837-1838.	0.6	3
66	Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression., 1997, 52, 20-25.		32
67	Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatment. Infection, 1996, 24, 419-425.	2.3	15
68	Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 1011-1014.	1.3	0